美国食品药品监督管理局（FDA）发布声明指出，Moderna公司在疫苗临床试验过程中，未遵循该机构资深科学家的专业建议，对年龄在65岁及以上的参与者提供了低于标准水平的医疗护理方案。这一做法导致该年龄段受试者面临更高的严重疾病风险。
声明强调，FDA的职业科学家曾明确建议应确保高龄参与者获得符合标准的照护，但Moderna未予采纳，反而实施了次优的护理标准，从而可能对受试者健康造成不利影响。
美国食品药品监督管理局（FDA）发布声明指出，Moderna公司在疫苗临床试验过程中，未遵循该机构资深科学家的专业建议，对年龄在65岁及以上的参与者提供了低于标准水平的医疗护理方案。这一做法导致该年龄段受试者面临更高的严重疾病风险。
声明强调，FDA的职业科学家曾明确建议应确保高龄参与者获得符合标准的照护，但Moderna未予采纳，反而实施了次优的护理标准，从而可能对受试者健康造成不利影响。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.